Indian Patent Office Refuses Roche’s Divisional Applications On Herceptin
This article was originally published in PharmAsia News
Executive Summary
In another setback to Roche, the Indian Patent Office has abandoned a divisional patent application on Herceptin, a decision that could benefit both Mylan and its local partner Biocon.